SS-31 Research Data

Natural Aminos Research Formula of the Day — SS-31

Benefits

SS-31 (elamipretide) is a synthetic tetrapeptide that concentrates over 1,000-fold in the inner mitochondrial membrane, where it binds and stabilizes cardiolipin, the phospholipid that organizes the electron transport chain. By protecting cardiolipin, SS-31 reduces electron leak and reactive oxygen species (ROS) production, prevents mitochondrial swelling, and blocks the release of cytochrome c that triggers cell death — effects shown across aging, cardiac, pulmonary, and neurological research models.

In aged mouse muscle, elamipretide treatment rapidly improved ADP sensitivity and ATP production by acting directly on the adenine nucleotide translocator (ANT) and ATP synthase, and chronic dosing increased exercise tolerance, muscle mass, and fatigue resistance. In separate rodent models, SS-31 reduced pulmonary fibrosis and inflammation by suppressing the NLRP3 inflammasome, and improved learning and memory after both sleep deprivation and inflammatory (LPS) challenge by protecting hippocampal mitochondria and preserving synaptic signaling.

Uses

SS-31's most advanced use is in mitochondrial disease. As of September 2025, the FDA granted accelerated approval to elamipretide (brand name Forzinity) as the first-ever approved treatment for Barth syndrome, a rare genetic mitochondrial disease, based on improved knee extensor muscle strength in a randomized, placebo-controlled trial and its open-label extension. This makes SS-31 the first mitochondria-targeted therapeutic to reach FDA approval for any indication.

Beyond Barth syndrome, SS-31 has been studied in primary mitochondrial myopathy (PMM), heart failure, dry age-related macular degeneration, and a range of preclinical disease models including pulmonary fibrosis, cognitive impairment, atherosclerosis, and renal fibrosis — reflecting its broad role as a general mitochondrial-protective and antioxidant agent rather than a narrowly targeted drug.

Published Research

The clearest human evidence is the Barth syndrome program: a randomized, double-blind, placebo-controlled 12-week trial followed by a 192-week open-label extension (the basis for the TAZPOWER studies) showed improvements in knee extensor muscle strength, with clinical reporting describing gains of roughly 45% in muscle strength and 40% in heart function among treated patients, supporting the 2025 FDA accelerated approval.

The record outside Barth syndrome is mixed. MMPOWER-2, a smaller crossover trial in primary mitochondrial myopathy, showed a 19.8-meter improvement in 6-minute walk distance that fell just short of statistical significance, with secondary patient-reported outcomes reaching significance. That encouraging signal led to MMPOWER-3, a pivotal phase 3, randomized, placebo-controlled trial in 218 PMM patients — which did not meet its co-primary endpoints (6-minute walk distance and fatigue score) in the overall population. A post hoc analysis found a genotype-specific benefit: patients with nuclear DNA mitochondrial-maintenance defects showed real improvement in walk distance, while patients with mitochondrial DNA defects (the majority of the trial) did not, prompting a new follow-up phase 3 trial (NuPOWER) targeting that responsive subgroup specifically.

Preclinical mechanistic evidence is extensive and consistent: peer-reviewed rodent studies support SS-31's cardiolipin-stabilizing, antioxidant, anti-inflammatory (NLRP3 suppression), and neuroprotective effects across aging, pulmonary fibrosis, and cognitive-impairment models.

Why More Research Is Needed

What's actually proven: SS-31 has now cleared the highest bar available — FDA approval — for one specific, ultra-rare indication (Barth syndrome), based on real randomized human trial data. Its core mitochondrial mechanism (cardiolipin stabilization, ROS reduction, ANT/ATP synthase binding) is unusually well replicated across independent animal models and disease contexts, which is not typical for an experimental peptide.

What's still theory or unresolved: SS-31's benefit does not generalize cleanly across mitochondrial disease. The pivotal PMM trial failed on its main population, and the positive signal that remains is confined to a specific genetic subgroup (nDNA mitochondrial-maintenance defects) awaiting confirmation in a dedicated follow-up trial. That matters for how the broader wellness/longevity narrative around SS-31 should be read: the theory that a drug which stabilizes cardiolipin and reduces oxidative stress should help "mitochondrial health" broadly is mechanistically reasonable and consistently supported in animal models, but the one rigorous human test of that broader claim (MMPOWER-3) did not confirm it outside a narrow subgroup. Applications like general cognitive support, aging, pulmonary disease, or cardiac protection remain preclinical extrapolations from mechanism and animal data, not demonstrated human outcomes. The gap between "validated mechanism in rodents" and "validated benefit in humans outside Barth syndrome" is the central open question for SS-31 going forward.

Sources

PMC/PubMed — The Mitochondrially Targeted Peptide Elamipretide (SS-31) Improves ADP Sensitivity in Aged Mitochondria by Increasing Uptake Through the ANT

PMC — Elamipretide (SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages

PMC — Mitochondrial Antioxidant Elamipretide Improves Learning and Memory Impairment Induced by Chronic Sleep Deprivation in Mice

PMC — Elamipretide (SS-31) Improves Mitochondrial Dysfunction, Synaptic and Memory Impairment Induced by Lipopolysaccharide in Mice

Neurology / PMC — Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial

PMC — Genotype-Specific Effects of Elamipretide in Patients with Primary Mitochondrial Myopathy: Post Hoc Analysis of MMPOWER-3

PubMed — A Randomized Crossover Trial of Elamipretide in Adults with Primary Mitochondrial Myopathy (MMPOWER-2)

Pharmacy Times — FDA Grants Accelerated Approval to Elamipretide, First Treatment for Barth Syndrome (Sept. 2025)

United Mitochondrial Disease Foundation (UMDF) — FDA Approves First Mitochondrial Disease Therapy: Elamipretide for Barth Syndrome

Hashtags

#Peptidetherapy #PeptideResearch #PeptideScience #Biohacking #ResearchPeptides #ScienceBased #SS31 #Elamipretide #MitochondrialHealth #CellularHealth #RecoveryScience